Cargando…
Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
The standard treatment of early-stage Hodgkin lymphoma (ESHL) as recommended by most national guidelines is combined modality treatment (CMT) that includes a short course ABVD followed by a small field of low dose radiotherapy (RT). Recently a trend to treat patients with more chemotherapy alone has...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180027/ https://www.ncbi.nlm.nih.gov/pubmed/24939521 http://dx.doi.org/10.1007/s11899-014-0222-5 |
_version_ | 1782337170123522048 |
---|---|
author | Yahalom, Joachim |
author_facet | Yahalom, Joachim |
author_sort | Yahalom, Joachim |
collection | PubMed |
description | The standard treatment of early-stage Hodgkin lymphoma (ESHL) as recommended by most national guidelines is combined modality treatment (CMT) that includes a short course ABVD followed by a small field of low dose radiotherapy (RT). Recently a trend to treat patients with more chemotherapy alone has been promoted by some claiming that chemotherapy alone is good enough, and the overall survival is similar. These arguments need to be carefully examined, and the risk of more chemotherapy upfront and salvage considered. The suggestion that interim PET will identify patients that can have similar results with chemotherapy alone has recently been questioned by the results of both European and UK studies. It is the subject of this critical review. |
format | Online Article Text |
id | pubmed-4180027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-41800272014-10-08 Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy Yahalom, Joachim Curr Hematol Malig Rep Lymphomas (J Armitage, Section Editor) The standard treatment of early-stage Hodgkin lymphoma (ESHL) as recommended by most national guidelines is combined modality treatment (CMT) that includes a short course ABVD followed by a small field of low dose radiotherapy (RT). Recently a trend to treat patients with more chemotherapy alone has been promoted by some claiming that chemotherapy alone is good enough, and the overall survival is similar. These arguments need to be carefully examined, and the risk of more chemotherapy upfront and salvage considered. The suggestion that interim PET will identify patients that can have similar results with chemotherapy alone has recently been questioned by the results of both European and UK studies. It is the subject of this critical review. Springer US 2014-06-18 2014 /pmc/articles/PMC4180027/ /pubmed/24939521 http://dx.doi.org/10.1007/s11899-014-0222-5 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Lymphomas (J Armitage, Section Editor) Yahalom, Joachim Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy |
title | Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy |
title_full | Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy |
title_fullStr | Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy |
title_full_unstemmed | Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy |
title_short | Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy |
title_sort | chemotherapy only in early-stage hodgkin lymphoma: more relapses but “same” (or possibly worse) survival – reconsidering the misguided trend to omit radiotherapy |
topic | Lymphomas (J Armitage, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180027/ https://www.ncbi.nlm.nih.gov/pubmed/24939521 http://dx.doi.org/10.1007/s11899-014-0222-5 |
work_keys_str_mv | AT yahalomjoachim chemotherapyonlyinearlystagehodgkinlymphomamorerelapsesbutsameorpossiblyworsesurvivalreconsideringthemisguidedtrendtoomitradiotherapy |